7 search results
- Current search:
- Has podcast
- Genetic disorders
- Reset
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
Cochrane EvidencePublished 4 May 2017
The use of vibrating devices to help people with cystic fibrosis clear their airways of mucus
Review question We reviewed the evidence about the effect of vibrating devices (e.g. Flutter, acapella, cornet, Quake®, intrapulmonary percussive ventilation, high frequency chest wall oscillators (e.g. Vest®), VibraLung® and MetaNeb®) to help people with cystic fibrosis clear their airways of mucus. This is an update of a previously published review. Background People ... -
Cochrane EvidencePublished 20 Apr 2017
Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease
Review question What is the effect of hydroxyurea on clinical outcomes (changes in pain crises, life-threatening illnesses, survival, haemoglobin levels, quality of life and side effects) in people with sickle cell disease (SCD) of any genotype? Background SCD is an inherited genetic disorder that creates problems with haemoglobin (the substance ... -
Cochrane EvidencePublished 19 Jan 2017
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Review question What are the effects of ataluren and similar compounds (specific therapies for premature termination codon (class I) mutations) on clinical outcomes (quality of life, lung function and adverse effects) in people with cystic fibrosis? Background In people with cystic fibrosis, the gene encoding a protein called the cystic fibrosis ... -
Cochrane EvidencePublished 6 Oct 2016
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications
Review question We wished to determine if any educational interventions have helped people with sickle cell disease and their caregivers to improve their understanding of the disease, recognize its complications, improve their adherence to treatment, affect how they utilize healthcare and improve other social and psychological problems that they might ... -
Cochrane EvidencePublished 14 Jul 2015
Which therapies are the most effective to prevent the progression of autosomal dominant polycystic kidney disease?
Current clinical care for people who have autosomal dominant polycystic kidney disease (ADPKD) focuses on controlling future risks for need for dialysis and symptom management, mainly pain and bleeding. Newly discovered molecules that may slow kidney cyst growth has recently switched attention from care and treatment toward preventing disease progression ... -
Cochrane EvidencePublished 24 Apr 2014
Immune tolerance induction to destroy inhibitors in people with haemophilia A or B
Review question We reviewed evidence about the effect of immune tolerance induction to remove inhibitors in people with haemophilia A and B. Background Haemophilia A and B are inherited bleeding disorders, where affected people are missing a clotting factor in their blood, which is needed for normal blood clotting. Without this factor, people with ... -
Cochrane EvidencePublished 30 Apr 2013
Nebulisers for giving medication in cystic fibrosis
Nebulisers change a liquid medication into a mist so it can be breathed in. There are different types of nebuliser systems and no review has yet considered whether any nebuliser is better than another. 1. Conventional nebuliser systems - a machine sucks air in and pushes it out at high speed; a tube attaches the machine to a chamber holding the medication ...
